Development and antimicrobial susceptibility studies of in vitro monomicrobial and polymicrobial biofilm models with Aspergillus fumigatus and Pseudomonas aeruginosa

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Manavathu, Elias K ^a,b   Vager, Dora L ^a   Vazquez, Jose A ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CIPROFLOXACIN; ECHINOCANDIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIAL CELL; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BIOFILM; BROTH DILUTION; CELL CULTURE; CFU COUNTING; COCULTURE; COLONY FORMING UNIT; CONIDIUM; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; EMBEDDING; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS SPORE; IN VITRO STUDY; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MTT ASSAY; MYCELIAL GROWTH; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PSEUDOMONAS AERUGINOSA; SPECTROPHOTOMETRY; TEMPERATURE;

ASPERGILLUS FUMIGATUS; BACTERIA (MICROORGANISMS); BOVINAE; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ASPERGILLUS FUMIGATUS; BIOFILMS; COLONY COUNT, MICROBIAL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY; PSEUDOMONAS AERUGINOSA; SPECTROPHOTOMETRY; STAINING AND LABELING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84897971296     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-53     Document Type: Article

References (71)

1. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, Kitzweger E, Ruckser R, Haslberger AG, PLoS One 2011 6 28654 10.1371/journal.pone.0028654 22194876
2. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Charlson ES, Diamond JM, Bittinger K, Fitzgerald AS, Yadav A, Haas AR, Bushman FD, Collman RG, Am J Respir Crit Care Med 2012 186 536 545 10.1164/rccm.201204-0693OC 22798321
3. Oral and airway microbiota in HIV-infected pneumonia patients. Iwai S, Fei M, Huang D, Fong S, Subramanian A, Grieco K, Lynch SV, Huang L, J Clin Microbiol 2012 50 2995 3002 10.1128/JCM.00278-12 22760045
4. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Rolston KV, Bodey GP, Safdar A, Clin Infect Dis 2007 45 228 233 10.1086/518873 17578784
5. Polymicrobial lung infection in postrenal transplant recipient diagnosed by fine-needle aspiration cytology. Duggal R, Rajwanshi A, Gupta N, Lal A, Singhal M, Diagn Cytopathol 2010 38 294 296 19927360
6. Characterization of bacterial communities in venous insufficiency wounds by use of conventional culture and molecular diagnostic methods. Tuttle MS, Mostow E, Mukherjee P, Hu FZ, Melton-Kreft R, Ehrlich GD, Dowd SE, Ghannoum MA, J Clin Microbiol 2011 49 3812 3819 10.1128/JCM.00847-11 21880958
7. Longitudinal shift in diabetic wound microbiota correlates with prolonged skin defense response. Grice EA, Snitkin ES, Yockey LJ, Bermudez DM, Liechty KW, Segre JA, Proc Natl Acad Sci U S A 2010 107 14799 14804 10.1073/pnas. 1004204107 20668241
8. The microbiome in wound repair and tissue fibrosis. Scales BS, Huffnagle GB, J Pathol 2013 229 323 331 doi:10.1002/path.4118 10.1002/path.4118 23042513
9. Traumatic wound microbiome workshop. Kirkup BC Jr, Craft DW, Palys T, Black C, Heitkamp R, Li C, Lu Y, Matlock N, McQueary C, Michels A, Peck G, Si Y, Summers AM, Thompson M, Zurawski DV, Microb Ecol 2012 64 837 850 10.1007/s00248-012-0070-6 22622764
10. Analysis of the lung microbiome in the "healthy" smoker and in COPD. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, Martinez FJ, Huffnagle GB, PLoS One 2011 6 16384 10.1371/journal.pone.0016384 21364979
11. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE, PLoS One 2012 7 47305 10.1371/journal.pone.0047305 23071781
12. The lung tissue microbiome in chronic obstructive pulmonary disease. Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, Cooper J, Sin DD, Mohn WW, Hogg JC, Am J Respir Crit Care Med 2012 185 1073 1080 10.1164/rccm.201111-2075OC 22427533
13. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. Cabrera-Rubio R, Garcia-Nunez M, Seto L, Anto JM, Moya A, Monso E, Mira A, J Clin Microbiol 2012 50 3562 3568 10.1128/JCM.00767-12 22915614
14. The airway microbiome in cystic fibrosis and implications for treatment. Zemanick ET, Sagel SD, Harris JK, Curr Opin Pediatr 2011 23 319 324 10.1097/MOP.0b013e32834604f2 21494150
15. Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. Stressmann FA, Rogers GB, Klem ER, Lilley AK, Donaldson SH, Daniels TW, Carroll MP, Patel N, Forbes B, Boucher RC, Wolfgang MC, Bruce KD, J Clin Microbiol 2011 49 281 291 10.1128/JCM.01650-10 21068277
16. Comparing the microbiota of the cystic fibrosis lung and human gut. Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD, Gut Microbes 2010 1 85 93 10.4161/gmic.1.2.11350 21326915
17. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. Guss AM, Roeselers G, Newton IL, Young CR, Klepac-Ceraj V, Lory S, Cavanaugh CM, ISME J 2011 5 20 29 10.1038/ismej.2010.88 20631810
18. The polymicrobial nature of airway infections in cystic fibrosis: cangene gold medal lecture. Sibley CD, Surette MG, Can J Microbiol 2011 57 69 77 10.1139/W10-105 21326348
19. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML, Hampton TH, Karagas MR, Palumbo PE, Foster JA, Hibberd PL, O'Toole GA, MBio 2012 3 4 00251-12 doi:10.1128/mBio.00251-12 22911969
20. The Effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Amin R, Dupuis A, Aaron SD, Ratjen F, Chest 2011 137 171 176
21. Infections in patients with cystic fibrosis following lung transplantation. Kanj SS, Tapson V, Davis RD, Madden J, Browning I, Chest 1997 112 924 930 10.1378/chest.112.4.924 9377954
22. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC, Chest 2003 123 800 808 10.1378/chest.123.3.800 12628881
23. Aspergillus infection in lung transplant patients: incidence and prognosis. Iversen M, Burton CM, Vand S, Skovfoged L, Carlsen J, Milman N, Andersen CB, Rasmussen M, Tvede M, Eur J Clin Microbiol Infect Dis 2007 26 879 886 10.1007/s10096-007-0376-3 17874329
24. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L, Chest 2009 136 1554 1560 10.1378/chest.09-0132 19505987
25. The changing microbial epidemiology in cystic fibrosis. Lipuma JJ, Clin Microbiol Rev 2010 23 299 323 10.1128/CMR.00068-09 20375354
26. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Pihet M, Carrere J, Cimon B, Chabasse D, Delhaes L, Symoens F, Bouchara JP, Med Mycol 2009 47 387 397 10.1080/13693780802609604 19107638
27. Clinical significance of microbial infection and adaptation in cystic fibrosis. Hauser AR, Jain M, Bar-Meir M, McColley SA, Clin Microbiol Rev 2011 24 29 70 10.1128/CMR.00036-10 21233507
28. Foundation CF, Patient Registry 2008: Annual Data Report to the Center Directors Bethesda, MD: Cystic Fibrosis Foundation 2008
29. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. Valenza G, Tappe D, Turnwald D, Frosch M, Konig C, Hebestreit H, Abele-Horn M, J Cyst Fibros 2008 7 123 127 10.1016/j.jcf.2007.06.006 17693140
30. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Bakare N, Rickerts V, Bargon J, Just-Nubling G, Mycoses 2003 46 19 23 10.1046/j.1439-0507.2003.00830.x
31. Allergic bronchopulmonary aspergillosis. Patterson K, Strek ME, Proc Am Thorac Soc 2010 7 237 244 10.1513/pats.200908-086AL 20463254
32. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Moss RB, Curr Opin Pulm Med 2010 16 598 603 10.1097/MCP.0b013e32833e24a6 20720494
33. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R, Am J Respir Crit Care Med 2006 174 1211 1220 10.1164/rccm.200603- 423OC 16959918
34. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Jubin V, Ranque S, Stremler Le Bel N, Sarles J, Dubus JC, Pediatr Pulmonol 2010 45 764 771 10.1002/ppul.21240 20597074
35. Microbial ecology of the cystic fibrosis lung: does microflora type influence microbial loading? Moore JE, Shaw A, Millar BC, Downey DG, Murphy PG, Elborn JS, Br J Biomed Sci 2005 62 175 178 16411377
36. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. Millar FA, Simmonds NJ, Hodson ME, J Cyst Fibros 2009 8 386 391 10.1016/j.jcf.2009.08.003 19740710
37. Antibiotic resistance of bacterial biofilms. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O, Int J Antimicrob Agents 2010 35 322 332 10.1016/j.ijantimicag.2009.12.011 20149602
38. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Seidler MJ, Salvenmoser S, Muller FM, Antimicrob Agents Chemother 2008 52 4130 4136 10.1128/AAC.00234-08 18710910
39. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Olson ME, Ceri H, Morck DW, Buret AG, Read RR, Can J Vet Res 2002 66 86 92 11989739
40. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. Mowat E, Butcher J, Lang S, Williams C, Ramage G, J Med Microbiol 2007 56 1205 1212 10.1099/jmm.0.47247-0 17761484
41. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Beauvais A, Schmidt C, Guadagnini S, Roux P, Perret E, Henry C, Paris S, Mallet A, Prevost MC, Latge JP, Cell Microbiol 2007 9 1588 1600 10.1111/j.1462-5822.2007.00895.x 17371405
42. In vivo biofilm composition of Aspergillus fumigatus. Loussert C, Schmitt C, Prevost MC, Balloy V, Fadel E, Philippe B, Kauffmann-Lacroix C, Latge JP, Beauvais A, Cell Microbiol 2010 12 405 410 10.1111/j.1462-5822.2009.01409.x 19889082
43. Functional genomic profiling of Aspergillus fumigatus biofilm reveals enhanced production of the mycotoxin gliotoxin. Bruns S, Seidler M, Albrecht D, Salvenmoser S, Remme N, Hertweck C, Brakhage AA, Kniemeyer O, Muller FM, Proteomics 2010 10 3097 3107 10.1002/pmic.201000129 20645385
44. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. Mowat E, Rajendran R, Williams C, McCulloch E, Jones B, Lang S, Ramage G, FEMS Microbiol Lett 2010 313 96 102 10.1111/j.1574-6968.2010.02130.x 20964704
45. Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Moree WJ, Phelen VV, Wu CH, Bandeira N, Cornett DS, Duggan BM, Dorrestein PC, Proc Natl Acad Sci U S A 2012 109 13811 13816 10.1073/pnas.1206855109 22869730
46. Software SC, SPOT Basic Software User Guide (Version 4.7) 2008, SPOT Imaging Solutions, A Division of Diagnostic Instruments, Inc Sterling Heights, MI 48314, USA
47. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl- 2H-tetrazolium bromide assay. Jahn B, Martin E, Stueben A, Bhakdi S, J Clin Microbiol 1995 33 661 667 7751374
48. Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE, J Clin Microbiol 2000 38 2949 2954 10921957
49. The adsorption of thrombin to polypropylene tubes: the effect of polyethylene glycol and bovine serum albumin. Horne MK, Thromb Res 1985 37 201 212 10.1016/0049-3848(85)90047-7 3983899
50. Serum inhibits P. aeruginosa biofilm formation on plastic surfaces and intravenous catheters. Hammond A, Dertien J, Colmer-Hamood JA, Griswold JA, Hamood AN, J Surg Res 2010 159 735 746 10.1016/j.jss.2008.09.003 19482317
51. Azithromycin retards Pseudomonas aeruginosa biofilm formation. Gillis RJ, Iglewski BH, J Clin Microbiol 2004 42 5842 5845 10.1128/JCM.42.12.5842-5845. 2004 15583321
52. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepaca and P. aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Dales L, Ferris W, Vandemheen K, Aaron SD, Eur J Clin Microbiol Infect Dis 2009 28 1275 1279 10.1007/s10096-009-0774-9 19575248
53. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. Mulcahy LR, Burns JL, Lory S, Lewis K, J Bacteriol 2010 192 6191 6199 10.1128/JB.01651-09 20935098
54. High-level antibiotic resistance in Pseudomonas aeruginosa biofilm: the ndvB gene is involved in the production of highly glycerol-phosphorylated beta-(1- > 3)-glucans, which bind aminoglycosides. Sadovskaya I, Vinogradov E, Li J, Hachani A, Kowalska K, Filloux A, Glycobiology 2010 20 895 904 10.1093/glycob/cwq047 20348539
55. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Tre-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ, Int J Antimicrob Agents 2008 31 329 336 10.1016/j. ijantimicag.2007.12.005 18280117
56. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. Zhang L, Mah TF, J Bacteriol 2008 190 4447 4452 10.1128/JB.01655-07 18469108
57. Mechanisms of biofilm resistance to antimicrobial agents. Mah TF, O'Toole GA, Trends Microbiol 2001 9 34 39 10.1016/S0966-842X(00)01913-2 11166241
58. P. aeruginosa biofilms in CF infection. Wagner VE, Iglewski BH, Clin Rev Allergy Immunol 2008 35 124 134 10.1007/s12016-008-8079-9 18509765
59. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Drenkard E, Ausubel FM, Nature 2002 416 740 743 10.1038/416740a 11961556
60. The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm? Mowat E, Williams C, Jones B, McChlery S, Ramage G, Med Mycol 2009 47 Suppl 1 120 S126 18654926
61. Our current understanding of fungal biofilms. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J, Crit Rev Microbiol 2009 35 340 355 10.3109/10408410903241436 19863383
62. Molecular Basis of Biofilm Development by Pseudomonads. Toutain CM, Caiazza N. C., O,Toole, G. A, Microbial Biofilms Washington, DC, USA: ASM Press, American Society for Microbiology, G A O,Toole, Ghannoum M, 2004 43 63
63. A Short History of the Development of the Biofilm Concept. Costerton JW, Microbial Biofilms Washington, DC, USA: ASM Press, American Society for Microbiology, Ghannoum M, Toole GA, 2004 4 19
64. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. Mowat E, Lang S, Williams C, McCulloch E, Jones B, Ramage G, J Antimicrob Chemother 2008 62 1281 1284 10.1093/jac/dkn402 18819968
65. Bacterial and fungal pneumonias after lung transplantation. Campos S, Caramori M, Teixeira R, Afonso J Jr, Carraro R, Strabelli T, Samano M, Pego-Fernandes P, Jatene F, Transplant Proc 2008 40 822 824 10.1016/j. transproceed.2008.02.049 18455028
66. Mixed bacterial-fungal infections in the CF respiratory tract. Leclair LW, Hogan DA, Med Mycol 2010 48 Suppl 1 125 S132 21067324
67. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE, Sein T, Groll AH, Bacher J, Avila NA, Walsh TJ, J Infect Dis 2003 187 1834 1843 10.1086/375420 12792859
68. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. Manavathu EK, Alangaden GJ, Chandrasekar PH, J Antimicrob Chemother 2003 51 1423 1425 10.1093/jac/dkg242 12716776
69. Expression, purification and in vitro antifungal activity of acidic mammalian chitinase against Candida albicans, Aspergillus fumigatus and Trichophyton rubrum strains. Chen L, Shen Z, Wu J, Clin Exp Dermatol 2009 34 55 60 10.1111/j.1365-2230.2008.03092.x 19076793
70. Human antimicrobial peptides' antifungal activity against Aspergillus fumigatus. Lupetti A, van Dissel JT, Brouwer CP, Nibbering PH, Eur J Clin Microbiol Infect Dis 2008 27 1125 1129 10.1007/s10096-008-0553-z 18566844
71. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ, Antimicrob Agents Chemother 2001 45 3310 3321 10.1128/AAC.45.12.3310-3321.2001 11709302